Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Siena – page 15

225 clinical trials in Siena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Siena at a glance
225
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

225 trials in Siena

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:ACP-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic spontaneous urticaria

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Systemic lupus erythematosus

Not recruiting

Study on MK-6194 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-6194
  • Sponsor:Merck Sharp & Dohme LLC

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bexotegrast
  • Sponsor:Pliant Therapeutics Inc.

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Small cell lung cancer extensive stage

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Idiopathic pulmonary fibrosis

Not recruiting

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Siena

What the registry says about research in the country

01 Respiratory Research

Clinical investigations focusing on pulmonary conditions, including studies of treatments for idiopathic pulmonary fibrosis and chronic rhinosinusitis. Research also includes innovative approaches for respiratory syncytial virus prevention in older adults.

  • Pulmonary Fibrosis Treatment Studies
  • Chronic Rhinosinusitis Management
  • RSV Vaccine Development
02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced therapies for lung cancer, Merkel cell carcinoma, and hematological malignancies.

  • Non-Small Cell Lung Cancer Treatments
  • Leukemia Therapies
  • Novel Cancer Immunotherapies
03 Metabolic & Cardiovascular Research

Innovative trials examining treatments for heart failure prevention and obesity management, with focus on new therapeutic combinations and cardiovascular safety assessments.

  • Heart Failure Prevention
  • Obesity Management
  • Cardiovascular Risk Reduction
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.